On Tuesday June 9, Axios business editor Dan Primack and Axios markets reporter Courtenay Brown hosted conversations with New York Stock Exchange President Stacey Cunningham and Sweetgreen CEO Jonathan Neman to discuss how to keep businesses afloat during economic uncertainty and how to make structural changes that have lasting equitable effects.

Stacey Cunningham discussed how corporate America can improve racial equity at the C-Suite level. She also unpacked the NYSE's decision to close the trading floor out of public health concerns, and the subsequent impact on investors.

  • On diversity at the head of companies: "If you have more diversity on boards, you get input on how to change your company and how to change your structure. Having diverse board rooms is critical to finding solutions and really changing the status quo."
  • On safely reopening: "It cost investors millions of dollars a day when the floors were closed, which is another reason why we wanted to get back to offering that full level of service for our clients."

Jonathan Neman discussed Sweetgreen's decision to return their PPP loan and how they are uniquely positioned to take social action as a company.

  • On the resilience of their business model: "We've been able to get back a lot of our business. And I think in a weird way, we're very well positioned for the other side of this even though food and restaurants have been severely impacted."
  • On how companies can advance social change: "Our mission is building healthier communities by connecting people to real food. What can we do where we are uniquely positioned to be part of the solution? We cannot solve the whole problem ourselves, but there's parts of it where we are uniquely positioned to help...The first is food insecurity in low income and black neighborhoods. The second is going much deeper in support of black farmers and vendors and championing black farmers across the country. The third is creating time and space for our team members to vote."

In a View from the Top segment, Axios CEO & Co-founder Jim VandeHei spoke with Goldman Sachs Chief Learning Officer James Fulton about corporate social responsibility and the role of business leaders in social change.

  • "It's now very clear that we're an actor on a much larger landscape. Community takes on a much greater importance in the context within which leaders are operating. I think going forward, that's going to be even more important, seeing ourselves as a component of a large and complicated system."

Thank you Goldman Sachs for sponsoring this event.

Go deeper

4 mins ago - Podcasts

Lots of jobs, lots of questions

America added 4.8 million jobs in June, easily exceeding economist expectations, while the unemployment rate fell from 13.3% to 11.1%. But the jobs picture remains very murky, particularly as some states pause or roll back economy reopenings.

Axios Re:Cap digs into the jobs picture right now and where it's headed, with The Washington Post's Catherine Rampell.

Updated 30 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 3:30 p.m. ET: 10,763,604 — Total deaths: 517,667 — Total recoveries — 5,522,094Map.
  2. U.S.: Total confirmed cases as of 3:30 p.m. ET: 2,715,124 — Total deaths: 128,439 — Total recoveries: 729,994 — Total tested: 32,827,359Map.
  3. Public health: What we know about the immune response to coronavirus and what it means for a vaccine.
  4. Politics: Herman Cain hospitalized for COVID-19 after attending Trump Tulsa rally — Biden downplays jobs number, rebukes Trump for ignoring health crisis.
  5. States: Florida reports more than 10,000 new coronavirus cases — 5 states saw 27% spike in heart-related deaths in first 3 months of coronavirus pandemic.

The other immune responders to COVID-19

Illustration: Eniola Odetunde/Axios

Scientists are inching closer to understanding how antibodies and immune cells are unleashed by the body in response to the novel coronavirus.

Why it matters: Natural immunity differs from that afforded by vaccination but it offers clues for the design of effective vaccines and therapies.